A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer	Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder	Recruiting	Phase 1 / Phase 2	2026-08-13		NCT07042802

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Nanjing Leads Biolabs Co.,Ltd	13

13 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Anyang Tumor Hospital	Anyang	China	9
Beijing Obstetrics and Gynecology Hospital Capital Medical University	Beijing	China	1
Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Beijing	China	13
Fujian Cancer Hospital	Fuzhou	China	109
Harbin Medical University Cancer Hospital	Harbin	China	102
Shandong Cancer Hospital	Jinan	China	86
Sun Yat-sen University Cancer Center	Guangzhou	China	315
The Affiliated Hospital of Xuzhou Medical University	Xuzhou	China	16
The First Affiliated Hospital of Zhengzhou University	Zhengzhou	China	125
The First Hospital of China Medical University	Shenyang	China	43
Tianjin Medical University Cancer Institute &Hospital	Tianjin	China	2
Yunnan Cancer Hospital	Kunming	China	2
Zhejiang Cancer Hospital	Hangzhou	China	164